Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice.

Abstract

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib) or in advanced clinical trials. We have tested 45 FDA-approved kinase inhibitors in vitro against murine hepatitis virus (MHV) as a model of SARS-CoV-2 replication and identified 12 showing inhibition in the delayed brain tumor (DBT) cell line. Vandetanib, which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase showed the most promising results on inhibition versus toxic effect on SARS-CoV-2-infected Caco-2 and A549-hACE2 cells (IC50 0.79 μM) while also showing a reduction of > 3 log TCID50/mL for HCoV-229E. The in vivo efficacy of vandetanib was assessed in a mouse model of SARS-CoV-2 infection and statistically significantly reduced the levels of IL-6, IL-10, TNF-α, and mitigated inflammatory cell infiltrates in the lungs of infected animals but did not reduce viral load. Vandetanib rescued the decreased IFN-1β caused by SARS-CoV-2 infection in mice to levels similar to that in uninfected animals. Our results indicate that the FDA-approved vandetanib is a potential therapeutic candidate for COVID-19 positioned for follow up in clinical trials either alone or in combination with other drugs to address the cytokine storm associated with this viral infection.

• Authors: Ana C Puhl, Giovanni F Gomes, Samara Damasceno, Ethan J Fritch, James A Levi, Nicole J Johnson, Frank Scholle, Lakshmanane Premkumar, Brett L Hurst, Felipe LeeMontiel, Flavio P Veras, Sabrina S Batah, Alexandre T Fabro, Nathaniel J Moorman, Boyd L Yount, Rebekah Dickmander, Ralph Baric, Kenneth H Pearce, Fernando Q Cunha, José C Alves-Filho, Thiago M Cunha, Sean Ekins
• Journal: bioRxiv : the preprint server for biology (bioRxiv) (Dec 20 2021) United States
• PMID: 34981062 (Publication Type: Preprint)